Cogent Biosciences, Inc. (COGT) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
COGT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
COGT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export COGT earnings history in CSV or JSON format
Free sign-in required to download data
Cogent Biosciences, Inc. (COGT) Earnings Overview
As of May 8, 2026, Cogent Biosciences, Inc. (COGT) reported trailing twelve-month net income of -$354M, reflecting -3.7% year-over-year growth. The company earned $-5.26 per diluted share over the past four quarters.
Looking at the long-term picture, COGT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2015.
Cogent Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), MRUS (-$335M net income, -595.9% margin), PRAX (-$327M net income), COGT has comparable earnings metrics. Compare COGT vs KYMR →
COGT Earnings vs Peers
Earnings metrics vs comparable public companies
COGT Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$329M | -28.6% | -$333M | $-2.55 | - | - |
| 2024 | -$256M | -33.0% | -$276M | $-2.46 | - | - |
| 2023 | -$192M | -37.2% | -$208M | $-2.42 | - | - |
| 2022 | -$140M | -94.0% | -$148M | $-2.26 | - | - |
| 2021 | -$72M | +3.4% | -$76M | $-1.85 | - | - |
| 2020 | -$75M | -147.1% | -$82M | $-6.00 | -950.4% | -1044.3% |
| 2019 | -$30M | +12.3% | -$32M | $-3.97 | -134.6% | -143.0% |
| 2018 | -$35M | -35.5% | -$36M | $-5.55 | -354.8% | -369.9% |
| 2017 | -$25M | -40.7% | -$26M | $-3.45 | -304.9% | -312.8% |
| 2016 | -$18M | -174.9% | -$19M | $-2.45 | -285.2% | -300.1% |
See COGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COGT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COGT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCOGT — Frequently Asked Questions
Quick answers to the most common questions about buying COGT stock.
Is COGT growing earnings?
COGT EPS of $-5.26 reflects slowing growth at -3.7%, below the 5-year CAGR of N/A. TTM net income is $-354M. Expansion rate has moderated.
What are COGT's profit margins?
Cogent Biosciences, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are COGT's earnings?
COGT earnings data spans 2015-2025. The current earnings trend is -3.7% YoY. Historical data enables comparison across business cycles.